Overview

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Status:
Not yet recruiting
Trial end date:
2023-02-06
Target enrollment:
Participant gender:
Summary
This research study is evaluating the safety and efficacy of Baricitinib in treating Cutaneous Lichen Planus (LP).
Phase:
Phase 2
Details
Lead Sponsor:
Aaron R. Mangold